4.8 Review

Microfluidic formulation of nanoparticles for biomedical applications

Journal

BIOMATERIALS
Volume 274, Issue -, Pages -

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2021.120826

Keywords

Microfluidics; Nanoparticle; Drug delivery; Imaging

Funding

  1. Burroughs Wellcome Fund Career Award at the Scientific Interface (CASI)
  2. US National Institutes of Health (NIH) Director's New Innovator Award [DP2 TR002776]
  3. American Cancer Society [129784-IRG-16-188-38-IRG]
  4. National Institutes of Health [NCI R01 CA241661, NCI R37 CA244911, NIDDK R01 DK123049]
  5. Abramson Cancer Center (ACC)-School of Engineering and Applied Sciences (SEAS) [P30 CA016520]
  6. 2018 AACR-Bayer Innovation and Discovery Grant [18-80-44-MITC]
  7. Paul G. Allen Family Foundation (Reconstructing Concussion)
  8. NIH [R33 CA206907, R21-EB023989, RM1 HG010023, R21 MH118170, R61 AI147406]
  9. DOD [W81XWH1920002]
  10. Pennsylvania Department of Health [4100077083]
  11. NSF Graduate Research Fellowship [1845298]
  12. U.S. Department of Defense (DOD) [W81XWH1920002] Funding Source: U.S. Department of Defense (DOD)
  13. Direct For Education and Human Resources
  14. Division Of Graduate Education [1845298] Funding Source: National Science Foundation

Ask authors/readers for more resources

Nanomedicine has advanced significantly in clinical applications, with microfluidic devices showing potential for generating reproducible nanoparticle formulations. These formulations enhance biomedical applications with controlled physical properties, pointing towards future production scale-independent formulations through parallelization and multi-step reactions.
Nanomedicine has made significant advances in clinical applications since the late-20th century, in part due to its distinct advantages in biocompatibility, potency, and novel therapeutic applications. Many nanoparticle (NP) therapies have been approved for clinical use, including as imaging agents or as platforms for drug delivery and gene therapy. However, there are remaining challenges that hinder translation, such as non-scalable production methods and the inefficiency of current NP formulations in delivering their cargo to their target. To address challenges with existing formulation methods that have batch-to-batch variability and produce particles with high dispersity, microfluidics-devices that manipulate fluids on a micrometer scale-have demonstrated enormous potential to generate reproducible NP formulations for therapeutic, diagnostic, and preventative applications. Microfluidic-generated NP formulations have been shown to have enhanced properties for biomedical applications by formulating NPs with more controlled physical properties than is possible with bulk techniques-such as size, size distribution, and loading efficiency. In this review, we highlight advances in microfluidic technologies for the formulation of NPs, with an emphasis on lipid-based NPs, polymeric NPs, and inorganic NPs. We provide a summary of microfluidic devices used for NP formulation with their advantages and respective challenges. Additionally, we provide our analysis for future outlooks in the field of NP formulation and microfluidics, with emerging topics of production scale-independent formulations through device parallelization and multi-step reactions within droplets.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available